Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biophytis SA - American Depositary Share (NQ: BPTS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biophytis SA - American Depositary Share

< Previous 1 2 3 Next >
Biophytis is Deploying its Partnership Strategy in Obesity
Via ACCESSWIRE
Biophytis Announces Transfer of ADSs to OTC Market
Via ACCESSWIRE
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
Via ACCESSWIRE
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
Via ACCESSWIRE
Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
Via ACCESSWIRE
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Via ACCESSWIRE
Results of the Combined General Meeting on April 2, 2024
Via ACCESSWIRE
Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted
Via ACCESSWIRE
Biophytis Announces Receipt of Nasdaq Notice
Via ACCESSWIRE
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil
Via ACCESSWIRE
Biophytis Receives Notice of Delisting From Nasdaq and Announces It Will Request a Hearing Before the Nasdaq Hearings Panel
Via ACCESSWIRE
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations
Via ACCESSWIRE
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
Via ACCESSWIRE
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
Via ACCESSWIRE
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
Via ACCESSWIRE
Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia
Via ACCESSWIRE
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York
Via ACCESSWIRE
Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project
Via ACCESSWIRE
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
Via ACCESSWIRE
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
Via ACCESSWIRE
Biophytis Announces $3.8 Million Registered Direct Offering
Via ACCESSWIRE
Russell 2000 ETF Momentum Sparks Volatility In Small Caps
The iShares Russell 2000 ETF (NYSE: IWM) impressive upward momentum has led to a volume, attention, and volatility surge in the small-cap market. 
Via MarketBeat
Topics ETFs Initial Public Offering
Exposures Securities Market
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
Via ACCESSWIRE
Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
Via ACCESSWIRE
Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress
Via ACCESSWIRE
Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June
Via ACCESSWIRE
Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
Via ACCESSWIRE
Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference
Via ACCESSWIRE
Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.